Sign up for our complimentary
weekly e-journal

Main Newsletter
Mastery Series
Therapy Series
 
Bookmark and Share | Print Article | Items for the Week Previous | All Articles This Week | Next
This article originally posted and appeared in  DietObesityIssue 680

Artificial Sweeteners May Affect Blood Glucose Levels and Insulin Response

Sucralose, the artificial sweetener of Splenda®, was found to have an effect on the absorption of glucose and subsequent insulin secretion in non-diabetic, obese individuals....

Advertisement

M. Yanina Pepino, PhD, and colleagues out of Washington University School of Medicine, St. Louis, began looking at non-nutritive sweeteners such as Splenda® (sucralose) and the metabolic response following its ingestion. Previous studies have indicated metabolic effects in animal models but the actual effects of these sweeteners in people still remain uncertain.

Generally, artificial sweeteners were thought to have no effect on our metabolism nor increase the calorie intake making them a perfect substitute for sugar in diet products. Added in small amounts to our food, these artificial sweeteners interact with receptors on the tongue to provide that same sweet sensation as sugar. However, it has been noted that in animals, these artificial sweeteners bind to similar receptors in the mouth as those found along the GI tract and in the pancreas leading to insulin release and glucose absorption.

To better understand the potential effects of non-nutritive sweeteners in humans, Pepino's research group studied the effects on hormones and glucose of sucralose use in 17 morbidly obese, insulin sensitive individuals who have no prior use of the food additive. Using a randomized crossover design, researchers conducted a 5-hour modified oral glucose tolerance test upon two separate occasions. Patients either consumed sucralose or water 10 minutes prior to the first glucose administration. Prior to the second glucose administration, each patient drank the opposite of what they had in the first test.

In consideration of the study population, Pepino said, "Most of the studies of artificial sweeteners have been conducted in healthy, lean individuals…We wanted to study this population because these sweeteners frequently are recommended to them as a way to make their diets healthier by limiting calorie intake."

The authors reported a greater effect on the body's hormones and glucose regulation with the ingestion of sucralose compared to water. They also reported a greater incremental increase in peak plasma glucose levels followed by an average of 20% greater insulin secretion in patients who ingested sucralose. Following ingestion of sucralose, an average of 7% decrease in insulin clearance and a 23% decrease in insulin sensitivity was noted compared to water. The authors did not detect any significant differences between the effects of sucralose or water on glucagon-like peptide 1, glucose-dependent insulinotropic polypeptide or glucagon incremental AUC.

The authors concluded, "Our results indicate that this artificial sweetener is not inert -- it does have an effect." In regards to the clinical importance of their findings, Pepino said, "What these all mean for daily life scenarios is still unknown, but our findings are stressing the need for more studies…Whether these acute effects of sucralose will influence how our bodies handle sugar in the long term is something we need to know."

M. Y. Pepino, C. D. Tiemann, B. W. Patterson, B. M. Wice, S. Klein. Sucralose Affects Glycemic and Hormonal Responses to an Oral Glucose Load. Diabetes Care, 2013; DOI: 10.2337/dc12-2221 

Advertisement


 

Bookmark and Share | Print | Category | Home

This article originally posted 06 June, 2013 and appeared in  DietObesityIssue 680

Past five issues: SGLT-2 Inhibitors Special Edition July 2015 | Diabetes Clinical Mastery Series Issue 251 | Issue 791 | Diabetes Clinical Mastery Series Issue 250 | GLP-1 Special Editions July 2015 |

2015 Most Popular Articles:

Self-Monitoring of Blood Glucose: The Patient's Perspective
Posted July 10, 2015
The Impact of Glucagon-Like Peptide 1 Receptor Agonists on Weight Reduction
Posted July 10, 2015
Diet That Mimics Fasting Appears to Slow Aging
Posted July 03, 2015
Vitamin D3 Supplementation and Weight Loss Prevent Cancer in Older Women
Posted July 10, 2015
Evaluation of Cellphone Application that Records Readings from Glucometer
Posted July 10, 2015
Metformin May Increase Mortality in Advanced CKD among Type 2 Patients
Posted July 10, 2015
GLP-1 Receptor Agonists Reduce Bone Loss During Weight Loss
Posted July 17, 2015
Can the Insulin Patch Become a Reality?
Posted July 03, 2015
New Evidence Suggests Pioglitazone Reduces Dementia Risk 42%
Posted July 03, 2015
Ancestral Diets Can Determine Vulnerability to Type 2 Diabetes
Posted July 17, 2015


Browse by Feature Writer & Article Category.
A. Lee Dellon, MD | Aaron I. Vinik, MD, PhD, FCP, MACP | Beverly Price | Charles W Martin, DD | Derek Lowe, PhD | Dr. Brian Jakes, Jr. | Dr. Fred Pescatore | Dr. Tom Burke, Ph.D | Eric S. Freedland | Evan D. Rosen | Ginger Kanzer-Lewis | Greg Milliger | Kristina Sandstedt | Laura Plunkett | Leonard Lipson, M.A. | Louis H. Philipson | Maria Emanuel Ryan, DDS, PhD | Marilyn Porter, RD, CDE | Melissa Diane Smith | Michael R. Cohen, RPh, MS, ScD, FASHP | Paul Chous, M.A., OD | Philip A. Wood PhD | R. Keith Campbell, Professor, B.Pharm, MBA, CDE | Richard K. Bernstein, MD | Sheri R. Colberg PhD | Sherri Shafer | Stanley Schwartz, MD, FACP, FACE | Steve Pohlit | Steven V. Edelman, M.D. | Timothy S. Hollingshead |

Cast Your Vote
Do you have any patients on a dual therapy of a DPP-4 and a SGLT-2 who have reached their goal A1c?

CME/CE of the Week
Greet Van den Berghe, MD, PhD

Category: General Diabetes
Credits: 1.0